Breeding and Pregnancy in MDR1 Dogs: Genetic Counseling and Safe Medication

The breeder sent me a panicked email at eleven at night. She had a litter of six Collie puppies, three weeks old, and had just applied a topical flea product to the dam because she noticed fleas in the whelping box. Within hours, two of the nursing puppies became lethargic and unresponsive. The product contained selamectin. The dam was MDR1 mutant/mutant. And selamectin, absorbed through the skin and concentrated in the milk, was now flooding into puppies whose blood-brain barriers were not yet mature enough to protect them even if they had functional P-glycoprotein.

Both puppies survived after intensive supportive care. But the episode illustrated something that many breeders of herding dogs still do not fully appreciate: MDR1 sensitivity does not begin at the first veterinary visit. It begins at conception, shapes every medication decision during pregnancy and lactation, and follows each puppy through the most vulnerable weeks of life. Understanding these dynamics is not optional for anyone breeding MDR1-affected lines. It is a fundamental responsibility.

MDR1 Inheritance: What Every Breeder Must Understand

The MDR1 mutation follows autosomal recessive inheritance for full clinical sensitivity, though heterozygous carriers can show intermediate effects. Before planning any breeding involving herding breeds, both the sire and dam should be tested. The possible crosses and their outcomes are straightforward but the implications deserve careful consideration.

When both parents are Normal/Normal (N/N), all puppies will be N/N. No drug sensitivity concerns exist. When one parent is Normal/Mutant (N/M) and the other is N/N, statistically half the puppies will be N/N and half will be carriers (N/M). No puppies will be fully affected (M/M). When both parents are N/M carriers, the expected distribution is 25 percent N/N, 50 percent N/M, and 25 percent M/M. One in four puppies will have full drug sensitivity. When one parent is M/M and the other is N/N, all puppies will be carriers (N/M). None will be fully affected, but all will carry the mutation.

The cross that responsible breeders must think hardest about is Mutant/Mutant to anything other than Normal/Normal. An M/M crossed with an N/M carrier produces 50 percent M/M and 50 percent N/M puppies. An M/M to M/M cross produces 100 percent affected puppies. These crosses are not necessarily wrong, but they require the breeder to commit to testing every puppy and educating every buyer. For a comprehensive explanation of the mutation itself and how it disrupts drug transport, our guide on understanding the MDR1 gene mutation provides the molecular context.

Should Breeders Eliminate the MDR1 Mutation?

This question generates heated debate. Some argue that MDR1-affected dogs should never be bred. Others point out that in certain breeds, the mutation frequency is so high that eliminating all carriers and affected dogs would devastate the gene pool. Both perspectives contain valid points, but the answer requires nuance rather than dogma.

In Collies, roughly 70 percent of the breed carries at least one copy of the MDR1 mutation. In Australian Shepherds, the figure is around 50 percent. In these breeds, excluding all carriers from breeding programs would eliminate a massive proportion of the available gene pool, bringing with it the loss of desirable traits, increased inbreeding, and potentially new health problems caused by genetic bottlenecking.

The more practical approach is to breed responsibly with knowledge. Test every breeding animal. Make informed crosses that minimize the production of M/M puppies when possible. When M/M puppies are produced, ensure buyers receive thorough education about drug safety. And never, under any circumstances, breed without knowing the MDR1 status of both parents. The breed prevalence statistics help breeders understand the scope of the challenge in their specific breed.

In breeds with lower mutation frequencies, such as German Shepherds where prevalence is around 10 percent, selective breeding against the mutation is more feasible and arguably more appropriate. When carrier frequency is low enough that N/N mates are readily available, there is less justification for producing affected puppies.

Pre-Breeding Health Screening and MDR1 Testing

MDR1 testing should be part of every pre-breeding health screening panel for at-risk breeds. The test is a simple cheek swab or blood sample that provides definitive results within one to two weeks. Several laboratories offer the test, and the cost is modest relative to the investment involved in breeding.

Test results are permanent. A dog tested once as N/N, N/M, or M/M will carry that genotype for life. There is no reason to retest, and results from any accredited laboratory are universally accepted. Our detailed guide on MDR1 testing procedures covers sample collection, lab options, and result interpretation for breeders.

Share test results openly. Reputable breeders publish their dogs' MDR1 status alongside hip scores, eye certifications, and other health clearances. Transparency builds trust with puppy buyers and advances breed health. Hiding or failing to disclose MDR1 status is not just irresponsible, it puts puppies at risk.

Medications During Pregnancy: What Is Safe?

Pregnancy in an MDR1-affected bitch requires careful medication management. The dam's drug sensitivity means that any P-glycoprotein substrate medication will reach higher concentrations in her brain. But there is a second concern: some of these drugs can also cross the placental barrier and affect developing fetuses.

P-glycoprotein is expressed in the placenta, where it normally functions as a protective pump that limits fetal drug exposure. In M/M dams, placental P-glycoprotein is non-functional, meaning fetuses receive higher drug doses than they would in a normal pregnancy. This double vulnerability, the dam's brain sensitivity plus the fetus's increased exposure, makes medication choices during pregnancy critically important.

Routine parasite prevention during pregnancy is the most common medication concern. Heartworm prevention must continue through pregnancy, as heartworm infection poses far greater risk than a properly dosed preventative. Milbemycin oxime at standard heartworm prevention doses is generally considered safe even in MDR1-affected dogs, as the problem doses are many times higher than prevention doses. However, confirm this with your veterinarian for your specific patient.

Flea and tick prevention during pregnancy should avoid all macrocyclic lactone-based topicals. The newer isoxazoline products do not interact with P-glycoprotein, but their safety during pregnancy has not been extensively studied in dogs. Many reproductive specialists recommend mechanical flea control such as frequent combing and environmental treatment rather than any systemic product during gestation.

Whelping Day: Anesthesia and Emergency Preparedness

Most whelpings proceed without intervention. But when they do not, the dam may need sedation, anesthesia for cesarean section, or pain management. All of the standard MDR1 anesthesia considerations apply, with the additional complexity of fetal safety.

If a cesarean section becomes necessary, the anesthetic protocol should follow MDR1-safe guidelines. Propofol for induction and isoflurane for maintenance are safe. Avoid acepromazine for pre-medication. Dexmedetomidine is a better choice, though its use very close to delivery requires consideration of fetal effects. Local or regional anesthesia, particularly epidural analgesia, is excellent for cesarean delivery in MDR1 dams because it minimizes systemic drug exposure to both dam and neonates.

Discuss the possibility of emergency cesarean section with your veterinarian before the due date. Having an MDR1-safe anesthetic plan already documented saves critical time if an emergency occurs at two in the morning when the on-call veterinarian may not be familiar with your dog's history.

Lactation and Nursing Puppies: The Hidden Danger

This is where many breeders get caught off guard. Medications given to the dam can pass into milk and be ingested by nursing puppies. In a normal situation, the puppies' own P-glycoprotein and blood-brain barrier provide some protection. But neonatal puppies have immature blood-brain barriers regardless of their MDR1 genotype. The barrier does not fully mature until approximately three to four weeks of age.

This means that during the first month of life, all puppies, even those who are genetically N/N, have limited brain protection against P-glycoprotein substrate drugs. Combine this developmental vulnerability with the higher drug concentrations in milk from an MDR1-affected dam, and you have a recipe for neonatal toxicity. The case I described at the opening of this article is a textbook example.

During lactation, the dam should receive no P-glycoprotein substrate medications unless absolutely necessary and prescribed by a veterinarian who understands both the MDR1 concern and the neonatal risk. This includes topical products that can be absorbed systemically. Flea products applied to the nursing dam's skin can reach nursing puppies through direct contact, ingestion during grooming, and milk transfer.

Puppy Deworming Protocols: Getting It Right

Standard puppy deworming begins at two weeks of age and continues at regular intervals. The most commonly used puppy dewormer is pyrantel pamoate, which is not a P-glycoprotein substrate and is safe for MDR1-affected puppies at standard doses. This is the appropriate first-line dewormer for litters from MDR1-affected lines.

Fenbendazole, used for giardia and certain roundworms, is also safe regardless of MDR1 status. It does not interact with P-glycoprotein and can be used at standard dosing in young puppies.

The danger comes when breeders use ivermectin-based dewormers for puppies. Some older deworming protocols call for ivermectin, and some breeders still use livestock ivermectin products diluted for puppies. This practice is dangerous in any MDR1-positive litter and should be absolutely avoided. Even at carefully calculated doses, the margin of safety in an M/M puppy with an immature blood-brain barrier is unacceptably narrow. For a thorough understanding of which macrocyclic lactones pose risk and at what doses, review our guide to macrocyclic lactones to avoid.

Begin heartworm prevention at the appropriate age, typically six to eight weeks, using products verified as safe at prevention doses. Discuss timing and product selection with your veterinarian. If puppies have been tested and their individual MDR1 genotypes are known, this guides product selection. If testing has not yet been performed, treat every puppy in the litter as potentially M/M until proven otherwise.

When to Test Puppies

If both parents are N/N, there is no need to test puppies for MDR1 since they will all be N/N. If one parent is N/M and the other is N/N, individual puppies may be N/N or N/M. Testing is informative but not urgent because no puppies will be M/M. If both parents are N/M or if either parent is M/M, testing puppies before they leave for their new homes is strongly recommended.

Cheek swab testing can be performed reliably once puppies are eating solid food, typically around four to five weeks of age. Some laboratories accept samples from younger puppies, but the reliability of very early swabs can vary. Blood-based testing can be done at any age but requires a veterinary blood draw.

Many breeders include MDR1 test results in their puppy packets alongside vaccination records, health certificates, and contract documents. This practice ensures that new owners have the information from day one and can share it immediately with their veterinarian. Sending puppies home without MDR1 status information when the parents are known carriers or affected is negligent.

Educating Puppy Buyers

Breeders have a responsibility that extends beyond producing healthy puppies. They must equip new owners with the knowledge to keep those puppies safe. For MDR1-affected breeds, this means every puppy buyer should leave with a clear understanding of what MDR1 means, which medications to avoid, and what to tell their veterinarian.

Provide written materials. Verbal explanations at puppy pickup are often forgotten in the excitement of bringing a new dog home. A printed document that explains MDR1 sensitivity, lists dangerous medications, and includes the puppy's test results gives the new owner a reference they can hand directly to their veterinarian. The complete drug list for MDR1 dogs is a resource many breeders include in their puppy packets.

Follow up. A message or call a week after the puppy goes home, asking whether the new owner has established veterinary care and shared the MDR1 information, reinforces the importance of this issue. Many new owners are overwhelmed with information at pickup and may not act on everything immediately. A gentle reminder can prevent a dangerous gap.

Genetic Counseling for Breeding Programs

For breeders managing ongoing programs in high-prevalence breeds, MDR1 is one piece of a complex genetic puzzle. It must be weighed against all other health and conformation priorities. A breeding program that eliminates MDR1 at the cost of introducing hip dysplasia or losing essential breed type has not improved the breed.

Work with a veterinary geneticist or breed health advisor when making complex breeding decisions. The goal is to reduce the frequency of the M/M genotype in the population over time while maintaining genetic diversity and overall health. This requires strategic pairing decisions that consider the full genetic profile of each dog, not just MDR1 status in isolation. For detailed guidance on which breeds carry the mutation and at what frequencies, MDR1 Gene Guide provides breed-specific data that helps breeders assess the genetic landscape in their breeding population.

Record keeping matters enormously. Track every breeding dog's MDR1 status, every puppy's test result, and the genotype outcomes of every litter. Over generations, this data reveals whether your program is moving in the right direction. Breeding databases and pedigree software that accommodate health test results make this tracking manageable.

The Breeder's Veterinary Partnership

Establish a relationship with a veterinarian who understands MDR1 and its implications for reproduction. Not every general practitioner has extensive experience with MDR1 management during pregnancy and lactation. If your regular veterinarian is unfamiliar with the specifics, ask for a referral to a reproductive specialist or a veterinarian with pharmacological expertise.

Before breeding, schedule a consultation specifically to discuss MDR1 management through pregnancy, whelping, and the neonatal period. Document the agreed-upon protocols for parasite prevention during gestation, emergency cesarean section anesthesia, lactation medication restrictions, and puppy deworming schedules. Having these protocols in writing prevents confusion when decisions need to be made quickly.

If complications arise during pregnancy or whelping, having an established relationship with a veterinarian who already understands your dog's MDR1 status eliminates the need to explain the situation during a crisis. The veterinary team can act immediately with appropriate drug selections because the groundwork was laid months earlier.

Neonatal Puppy Monitoring

During the first four weeks of life, monitor nursing puppies closely for any signs of neurological depression that could indicate drug transfer through milk. Normal neonatal puppies spend most of their time sleeping and nursing, which can make subtle toxicity signs difficult to detect. However, there are indicators that something is wrong.

A puppy that suddenly stops nursing when it was previously feeding well is a red flag. Excessive lethargy beyond the normal neonatal sleep pattern, failure to respond to stimulation, and decreased muscle tone all warrant immediate veterinary attention. If the dam has received any medication, no matter how routine it might seem, mention this to the veterinarian.

Weigh puppies daily during the first two weeks and every other day thereafter. Weight gain is the most reliable indicator of neonatal health. A puppy that stops gaining or loses weight needs evaluation. While many causes exist for neonatal failure to thrive, drug exposure through milk should be considered in any litter from an MDR1-affected dam who has received medication.

Moving Forward Responsibly

Breeding MDR1-affected dogs is not irresponsible. Breeding them without knowledge, without testing, and without plans is irresponsible. The genetic tools available today make it possible to manage MDR1 with precision. Test every breeding animal. Know the expected genotype ratios before puppies arrive. Plan medication protocols in advance. Test puppies. Educate buyers.

The breeds that carry MDR1 are among the most beloved and capable working dogs in the world. Collies, Australian Shepherds, Shetland Sheepdogs, and their relatives bring extraordinary intelligence, loyalty, and beauty to the families who own them. These breeds deserve breeders who approach MDR1 not as an insurmountable problem but as a manageable genetic variable that requires attention, knowledge, and commitment.

Every puppy that leaves your program with a known MDR1 status and an educated owner is a puppy protected from preventable tragedy. That is the standard. Meet it.